Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by DJDawgon Jan 25, 2024 11:56am
178 Views
Post# 35845146

RE:RE:RE:RE:RE:RE:RE:CG Oncology phase 3 results impossible for TLT to beat?

RE:RE:RE:RE:RE:RE:RE:CG Oncology phase 3 results impossible for TLT to beat?High success rate is tricky. Many patients have been through the long series of BCG instillations and then had that fail. Now to be offered another long series (weekly x 6 weeks, then 3 more at 3m, 6m, 9m and 12m) is a lot to take in. Many patients don't actually live near a urology care centre so there is lots of commuting to consider.

In phase 1b, Ruvidar was used on 3 patients. 2 of them had a total of 5 tumour sites on bladder wall and were cured after one treatment (cured in as far as not recurrence when followed for 18 m afterwards). That is a powerful thing. No oncologist on the planet would consider one dose of an immune agent as able to do anything at all. Hence the 18 treatments for most of them, in the first year.

I hope that whoever is writing up these applications for TLT can highlight that all the rest do not show a durable response when you stop the constant instillations. For the CG oncology data they have not resported outcomes on any patients who has gone beyond 3m from last treatment.

All the agents that have reported so far show significant fall off after 450 days. N-803 combined with BCG has a CR of 24-30% by 24m with ongoing fall off. . Compared to the touted 70% initial CR.

If they could get GBM going then that is two things in the pipeline as another selling point.
<< Previous
Bullboard Posts
Next >>